Assessment of preoperative serum prolidase activity in epithelial ovarian cancer

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 147, Issue 1, 2009, Pages 97-100

  Camuzcuoglu, Hakan ^a   Arioz, Dagistan Tolga ^b   Toy, Harun ^a   Kurt, Sefa ^c   Celik, Hakim ^a   Aksoy, Nurten ^a  

^a HARRAN UNIVERSITY   (Turkey)

^b AFYON KOCATEPE UNIVERSITY   (Turkey)

^c Aegean Maternity and Women's Health Hospital   (Turkey)

Author keywords

Epithelial ovarian cancer; Extracellular matrix; Oxidative stress; Prolidase activity

Indexed keywords

CA 125 ANTIGEN; PROLINE DIPEPTIDASE;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; OVARY CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

EID: 71749099973     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2009.07.012     Document Type: Article

References (30)

1. Parkin D.M., Pinasi P., and Ferlay J. Global cancer statistics. CA: Cancer J Clin 49 (1999) 33-64
2. Ahmed F.Y., Wiltshaw E., A'Hern R.P., et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 14 (1996) 2968-2975
3. Kamat A.A., Fletcher M., Gruman L.M., et al. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 12 (2006) 1707-1714
4. Liotta L.A., Rao C.N., and Barsky S.H. Tumor invasion and the extracellular matrix. Lab Invest 49 (1983) 636-649
5. Moore D.H., Allison B., Look K.Y., Sutton G.P., and Bigsby R.M. Collagenase expression in ovarian cancer cell lines. Gynecol Oncol 65 (1997) 78-82
6. Rauvala M., Puistola U., and Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 99 (2005) 656-663
7. Maatta M., Talvensaari-Mattila A., Turpeenniemi-Hujanen T., and Santala M. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res 27 (2007) 2753-2758
8. Manenti L., Paganoni P., Floriani I., et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 39 (2003) 1948-1956
9. Liotta L.A., Tryggvason K., Garbisa S., Hart I., Foltz C.M., and Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284 (1980) 67-68
10. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W.G., and Quaranta V. Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 277 (1997) 225-228
11. Surazynski A., Donald S.P., Cooper S.K., et al. Extracellular matrix and HIF-1 signaling: the role of prolidase. Int J Cancer 122 (2008) 1435-1440
12. Palka J., Surazynski A., Karna E., et al. Prolidase activity disregulation in chronic pancreatitis and pancreatic cancer. Hepatogastroenterology 49 November-December(48) (2002) 1699-1703
13. Cechowska-Pasko M., Pakła J., and Wojtukiewicz M.Z. Enhanced prolidase activity and decreased collagen content in breast cancer tissue. Int J Exp Pathol 87 (2006) 289-296
14. Palka J.A., and Phang J.M. Prolidase activity in fibroblasts is regulated by interaction of extrecelluar matrix with cell surface integrine receptors. J Cell Biochem 67 (1977) 166-175
15. Surazynski A., Miltyk W., Palka J., and Phang J.M. Prolidase-dependent regulation of collagen biosynthesis. Amino Acids 35 (2008) 731-738
16. Yildiz A., Demirbag R., Yilmaz R., Gur M., Altiparmak I.H., and Akyol S. The association of serum prolidase activity with the presence and severity of coronary artery disease. Coronary Artery Dis 19 (2008) 319-325
17. Guszczyn T., and Sobolewski K. Deregulation of collagen metabolism in human stomach cancer. Pathobiology 71 (2004) 308-313
18. Karna E., Surazynski A., and Palka J. Collagen metabolism disturbances are accompanied by an increase in prolidase activity in lung carcinoma planoepitheliale. Int J Exp Pathol 81 (2000) 341-347
19. Myara I., Charpentier C., and Lemonnier A. Optimal conditions for prolidase assay by praline colorimetric determination: application to imminodipeptiduria. Clin Chim Acta 125 (1982) 193-205
20. Chinard F.P. Photometric estimation of proline and ornithine. J Biol Chem 199 (1952) 91-95
21. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38 (2005) 1103-1111
22. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 37 (2004) 112-119
23. Obayashi Y., Yabushita H., Kanyama K., et al. Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer. Oncol Rep 19 (2008) 1245-1251
24. Garzetti G.G., Ciavattini A., Lucarini G., et al. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res 15 (1995) 2799-2804
25. Santala M., Simojoki M., Risteli J., Risteli L., and Kauppila A. Type I and type III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer. Clin Cancer Res 5 (1999) 4091-4096
26. Surazynski A., Sienkiewicz P., Wolczynski S., and Palka J. Differential effects of echistatin and thrombin on collagen production and prolidase activity in human dermal fibroblasts and their possible implication in beta1-integrinmediated signaling. Pharmacol Res 51 (2005) 217-221
27. Casey R.C., and Skubitz A.P. CD44 and beta1 integrins mediate ovarian carcinoma cell migration toward extracellular matrix proteins. Clin Exp Metast 18 (2000) 67-75
28. Tozer E.C., Hughes P.E., and Loftus J.C. Ligand binding and affinity modulation of integrins. Biochem Cell Biol 74 (1996) 785-798
29. Strobel T., and Cannistra S.A. Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 73 (1999) 362-367
30. Camuzcuoglu H., Arioz D.T., Toy H., Kurt S., Celik H., and Erel O. Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer. Gynecol Oncol 112 (2009) 481-485